[해외논문]
CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies
Medical and pediatric oncology ,
v.35 no.6 ,
2000년, pp.677 - 682
Donovan, John
(Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts)
,
Temel, Jennifer
(Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts)
,
Zuckerman, Amy
(Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts)
,
Gribben, John
(Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts)
,
Fang, Junjie
(Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania)
,
Pierson, Giuliana
(Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania)
,
Ross, Amy
(Diagnostics Division, Nexell Therapeutics, Inc. Irvine, California)
,
Diller, Lisa
(Department of Pediatric Oncology, Dana-Farber Cancer Institute and Department of Medicine, Children's Hospital, Boston, Massachusetts)
,
Grupp, Stephan A.
(Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Ph)
BackgroundThe suitability of CD34 selection for purging peripheral blood progenitor cells (PBPC) collected from patients with neuroblastoma (NB) has been called into question, largely because of reports of detection of low levels of CD34 on the surface of some NB cell lines and tumors.ProcedureWe us...
BackgroundThe suitability of CD34 selection for purging peripheral blood progenitor cells (PBPC) collected from patients with neuroblastoma (NB) has been called into question, largely because of reports of detection of low levels of CD34 on the surface of some NB cell lines and tumors.ProcedureWe used three approaches to address the issue of purging of NB from stem cell specimens and possible labeling of NB: 1) Flow cytometric detection of CD34 on NB cell lines. We assessed CD34 expression using a panel of anti-CD34 monoclonal antibodies (MoAbs) including 9C5, 12.8, and QBend10 and showed no increase in labeling over secondary-only control. 2) Spiking experiments with the Isolex 50 system. NB cell lines were used to contaminate aliquots of PBPC collections, after which the products were purified using the Isolex 50. Purging of NB was assessed by quantitative multiplex RT-PCR (TaqMan system) using a tumor-specific transcript, GAGE. We demonstrated >2 logs of tumor cell depletion from these specimens. 3) Analysis of clinical specimens. PBPC pre- and post-CD34 selection were analyzed from patients treated on the CHP-594 transplant trial.ResultsIn nine specimens selected using the Ceprate LC CD34 selection system where tumor was detectable by immunocytochemistry preselection, we observed >2.4 to >4.6 logs of NB purging after selection. We then analyzed 23 aliquots of PBPC infused into patients post-CD34 selection and compared them to the product preselection; 20/23 specimens showed depletion of NB, although some level of GAGE message was observed in most post-CD34 selection specimens.ConclusionThese data show that purging of NB from PBPC specimens using CD34 selection is feasible, yielding infused products that are negative at the level of ICC but often positive at the level of RT-PCR. Med. Pediatr. Oncol. 35:677–682, 2000. © 2000 Wiley-Liss, Inc.
BackgroundThe suitability of CD34 selection for purging peripheral blood progenitor cells (PBPC) collected from patients with neuroblastoma (NB) has been called into question, largely because of reports of detection of low levels of CD34 on the surface of some NB cell lines and tumors.ProcedureWe used three approaches to address the issue of purging of NB from stem cell specimens and possible labeling of NB: 1) Flow cytometric detection of CD34 on NB cell lines. We assessed CD34 expression using a panel of anti-CD34 monoclonal antibodies (MoAbs) including 9C5, 12.8, and QBend10 and showed no increase in labeling over secondary-only control. 2) Spiking experiments with the Isolex 50 system. NB cell lines were used to contaminate aliquots of PBPC collections, after which the products were purified using the Isolex 50. Purging of NB was assessed by quantitative multiplex RT-PCR (TaqMan system) using a tumor-specific transcript, GAGE. We demonstrated >2 logs of tumor cell depletion from these specimens. 3) Analysis of clinical specimens. PBPC pre- and post-CD34 selection were analyzed from patients treated on the CHP-594 transplant trial.ResultsIn nine specimens selected using the Ceprate LC CD34 selection system where tumor was detectable by immunocytochemistry preselection, we observed >2.4 to >4.6 logs of NB purging after selection. We then analyzed 23 aliquots of PBPC infused into patients post-CD34 selection and compared them to the product preselection; 20/23 specimens showed depletion of NB, although some level of GAGE message was observed in most post-CD34 selection specimens.ConclusionThese data show that purging of NB from PBPC specimens using CD34 selection is feasible, yielding infused products that are negative at the level of ICC but often positive at the level of RT-PCR. Med. Pediatr. Oncol. 35:677–682, 2000. © 2000 Wiley-Liss, Inc.
주제어
참고문헌 (19)
N Engl J Med Matthay 341 1165 1999 10.1056/NEJM199910143411601
Lancet Brenner 341 85 1993 10.1016/0140-6736(93)92560-G
Blood Freedman 94 3325 1999 10.1182/blood.V94.10.3325.422k13_3325_3333
J Clin Oncol Civin 14 2224 1996 10.1200/JCO.1996.14.8.2224
J Clin Oncol Shpall 12 28 1994 10.1200/JCO.1994.12.1.28
J Neuroimmunol Hafer 96 201 1999 10.1016/S0165-5728(99)00030-2
J Neuroimmunol Voigt 78 117 1997 10.1016/S0165-5728(97)00088-X
J Clin Oncol Brodeur 11 1466 1993 10.1200/JCO.1993.11.8.1466
J Clin Oncol Grupp 18 2567 2000 10.1200/JCO.2000.18.13.2567
N Engl J Med Moss 324 219 1991 10.1056/NEJM199101243240403
J Clin Pathol Rogers 42 422 1989 10.1136/jcp.42.4.422
Clin Cancer Res Cheung 3 821 1997
Greenfield 1996 et al. CD34 expression on pediatric solid tumors. Proc ASPHO, 1996.
Eur J Cancer Lode 33 2024 1997 10.1016/S0959-8049(97)00243-8
Med Pediatr Oncol Tchirkov 30 228 1998 10.1002/(SICI)1096-911X(199804)30:4<228::AID-MPO4>3.0.CO;2-I
J Hematother Handgretinger 6 235 1997 10.1089/scd.1.1997.6.235
Blood Kanold 92 445a 1998
Med Pediatr Oncol Kanold 35 1 2000 10.1002/1096-911X(200007)35:1<1::AID-MPO1>3.0.CO;2-C
Med Ped Oncol Grupp 35 696 2000 10.1002/1096-911X(20001201)35:6<696::AID-MPO46>3.0.CO;2-0
더보기
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.